This trial is testing the safety of using an investigational drug to treat CAR T cell related CRS and HLH-like syndrome.
- Hemophagocytic Lymphohistiocytosis
- Cytokine Release Syndrome
1 Primary · 0 Secondary · Reporting Duration: 28 days
Awards & Highlights
1 Treatment Group
1 of 1
10 Total Participants · 1 Treatment Group
Primary Treatment: Tadekinig alfa (IL-18BP) · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are medical practitioners currently enrolling participants for this experiment?
"According to clinicaltrials.gov, the recruitment phase of this study is ongoing with postings appearing as early April 17th 2022 and the most recent update being on July 5th 2022." - Anonymous Online Contributor
How many participants have been recruited to join this clinical trial?
"Affirmative. Clinicaltrials.gov specifics that this experiment is recruiting, with the first post dating back to April 17th 2022 and the most recent update occurring on July 5th 2022. This research necessitates 10 volunteers from 1 location." - Anonymous Online Contributor